049
ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

W. Xu[1] | S. Yang[2] | K. Zhou[3] | L. Pan[4] | Z. Li[5] | J. Zhou[6] | S. Gao[7] | D. Zhou[8] | J. Hu[9] | R. Feng[10] | H. Huang[11] | M. Ji[12] | H. Guo[12] | J. Huang[13] | W. Novotny[13] | S. Feng[13] | J. Li[1]

[1]Hematology Department, Jiangsu Province Hospital, Nanjing, China; [2]Hematology Department, Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China; [3]Hematology Department, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; [4]Hematology Department, West China Hospital of Sichuan University, Chengdu, China; [5]Hematology Department, Tianjin Hematonosis Hospital, Tianjin, China; [6]Hematology Department, Wuhan Tongji Hospital, Wuhan, China; [7]Hematology Department, The 1st Hospital of Jilin University, Changchun, China; [8]Hematology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; [9]Hematology Department, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China; [10]Hematology Department, Nanfang Hospital of Southern Medical University, Guangzhou, China; [11]Hematology Department, The 1st Hospital of Soochow University, Suzhou, China; [12]Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China; [13]Clinical Development, BeiGene USA, Inc., San Mateo, United States

Introduction: Zanubrutinib is a selective and irreversible BTK inhibitor that has demonstrated potent inhibition of BTK preclinically, with minimal, off-target inhibition of other kinases. Complete and sustained BTK occupancy in both blood and lymph node biopsies from patients treated with zanubrutinib at 160 mg twice daily (BID) was observed in a phase 1 clinical trial.

Methods: In this single-arm, multicenter phase 2 study (ClinicalTrials.gov NCT03206918), zanubrutinib was given by mouth, 160 mg BID to patients with relapsed or refractory CLL/SLL until disease progression (PD) or unacceptable toxicity. Efficacy endpoints were assessed by independent review (IRC) in accordance with IWCLL guidelines (IWCLL, 2008) or the Lugano Classification (Cheson, 2014) for CLL and SLL, respectively.

Results: As of 14 December 2018, 91 pts (82 with CLL; 9 with SLL) were enrolled and treated at 11 centers in China. Baseline disease characteristics are summarized in the table. Median follow-up was 15.1 mo (range, 0.8-21.2 mo) with treatment discontinuation in 16 (17.6%) pts (8 due to AEs, 7 due to PD, and 1 due to pt withdrawal). A total of 83 pts (91.2%, 95% CI: 83.4, 91.6) achieved a best response of partial response with lymphocytosis (PR-L) or better according to investigators' assessment. Patients with del(17p) or TP53 mutation achieved a high

Baseline Disease Characteristics	N=91	
Median age, y (range)	61.0 (35-87)	
Male, n (%)	52 (57.1)	
Binet stage B or C (CLL pts), n (%)	77 (93.9)	
Stage IV (SLL pts), n (%)	7 (77.8)	
Del(17p), n (%)	17 (18.7)	
TP53 mutation, n (%)	20 (22.0)	
Del(17p) or TP53 mutation, n (%)	22 (24.2)	
Del(13q), n (%)	41 (45.1)	
Del(11q), n (%)	20 (22)	
Trisomy 12, n (%)	21 (23.1)	
IGHV unmutated, n (%)	51 (56.0)	
Lines of prior therapy, median (range)	1 (1-9)	
Efficacy[a]		
Complete response (CR), n (%)	4 (4.4)	
Nodular partial response (nPR), n (%)	2 (2.2)	
Partial response (PR), n (%)	60 (65.9)	
Partial response with lymphocytosis (PR-L), n (%)	17 (18.7)	
Stable disease (SD), n (%)	4 (4.4)	
Progressive disease (PD), n (%)	1 (1.1)	
Discontinued prior to 1st assessment, n (%)	3 (3.3)	
Safety		
Any TEAE, n (%)	91 (100)	
Serious AE, n (%)	30 (33.0)	
AE leading to treatment discontinuation, n (%)	8 (8.8)	
AE leading to death[b], n (%)	3 (3.3)	
Common Adverse Event	**Any Grade**	**Grade ≥3**
Neutrophil count decreased, n (%)	62 (68.1)	40 (44.0)
Upper respiratory tract infection, n (%)	41 (45.1)	9(9.9)
Purpura, n (%)	31 (34.1)	0 (0)
Platelet count decreased, n (%)	30 (33.0)	8 (8.8)
Haematuria, n (%)	27 (29.7)	0 (0)
Anaemia, n (%)	25 (27.5)	8 (8.8)
Hypokalaemia, n (%)	23 (25.3)	6 (6.6)

[a] Best response as assessed by the investigator. IRC-assessed efficacy outcomes are ongoing and will be presented.
[b] One of the patients with primary reason of death due to PD also reported a fatal AE of multiple organ dysfunction syndrome.

ORR (95.5%). Median time for achieving first response was 2.79 mo (range, 2.6-5.6 mo) among responders. Estimated PFS rate at 12 months was 80.9% (95% CI: 67, 89). The most frequently reported AEs are summarized in the table below. Major hemorrhage was reported in 2 patients (Gr 3, gastrointestinal hemorrhage and Gr 2 intracranial hemorrhage), which led to discontinuation of zanubrutinib. Four (4.4%) pts died within 30 days of their last dose of study drug, 2 due to PD and 2 due to AEs (pulmonary infection; cardiopulmonary failure).

Conclusions: Zanubrutinib was generally well-tolerated and resulted in a high response rate, including in patients with del(17p) or TP53 mutation.

Keywords: BTK inhibitors; chronic lymphocytic leukemia (CLL); zanubrutinib.

Disclosures: Ji, M: Employment Leadership Position: *Bei Gene, Associate Director of Clinical Development*; Stock Ownership: *Own BeiGene Stock*. **Guo, H:** Employment Leadership Position: *Executive Director of BeiGene*; Stock Ownership: *Own BeiGene Stock*. **Huang, J:** Employment Leadership Position: *CMO Hematology of BeiGene*. **Novotny, W:** Employment Leadership Position: *BeiGene Employee*; Stock Ownership: *Own BeiGene Stock*. **Feng, S:** Employment Leadership Position: *BeiGene USA Employee*; Stock Ownership: *Own BeiGene Stock*.